Henry Schein (NASDAQ:HSIC) Price Target Cut to $82.00 by Analysts at Mizuho

Henry Schein (NASDAQ:HSIC) had its price objective dropped by investment analysts at Mizuho from $88.00 to $82.00 in a report released on Wednesday, Marketbeat reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s price objective would indicate a potential upside of 10.47% from the company’s previous close.

A number of other research firms also recently commented on HSIC. Citigroup initiated coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 price objective for the company. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research note on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. UBS Group upped their price objective on shares of Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company upped their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $87.00.

Henry Schein Price Performance

HSIC stock traded down $0.15 during trading on Wednesday, hitting $74.23. The stock had a trading volume of 124,971 shares, compared to its average volume of 1,305,499. The company’s 50 day moving average price is $76.48 and its two-hundred day moving average price is $74.92. Henry Schein has a 1-year low of $61.94 and a 1-year high of $89.29. The stock has a market cap of $8.52 billion, a price-to-earnings ratio of 22.82, a price-to-earnings-growth ratio of 2.13 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the prior year, the company posted $1.15 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts forecast that Henry Schein will post 5.3 EPS for the current fiscal year.

Insider Buying and Selling at Henry Schein

In other news, CEO Stanley M. Bergman sold 43,812 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the sale, the chief executive officer owned 383,803 shares in the company, valued at approximately $31,207,021.93. The trade was a 10.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kurt P. Kuehn sold 2,844 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the sale, the director owned 15,420 shares of the company’s stock, valued at $1,217,563.20. The trade was a 15.57% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 105,911 shares of company stock worth $8,574,982. Company insiders own 0.89% of the company’s stock.

Institutional Investors Weigh In On Henry Schein

Large investors have recently modified their holdings of the stock. CYBER HORNET ETFs LLC acquired a new position in Henry Schein during the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein in the fourth quarter valued at approximately $30,000. Federated Hermes Inc. acquired a new stake in Henry Schein in the fourth quarter valued at approximately $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Henry Schein in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein News Summary

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q1 outperformance: Reported EPS $1.32 vs. $1.20 consensus and revenue $3.37B vs. $3.34B consensus; revenue +6.3% YoY and management cited market-share gains and gross-margin expansion driven by a strong dental business. Henry Schein Reports First Quarter 2026 Financial Results
• Positive Sentiment: Analyst takeaways: Multiple outlets note rising gross margins and 14.8% EPS growth versus prior year, reinforcing operational progress and underlying demand in dental/medical distribution. HSIC Q1 Earnings & Revenues Surpass Estimates, Gross Margin Rises
• Neutral Sentiment: Guidance reaffirmed but mixed: Management reaffirmed FY‑2026 EPS guidance of $5.230–$5.370 and revenue $13.6–13.8B (roughly in line with consensus), leaving the EPS midpoint slightly below some estimates — a neutral-to-mixed signal on future upside. Henry Schein reaffirms annual profit forecast, beats Q1 estimates on dental strength
• Neutral Sentiment: Call and disclosures: Management commentary and the full earnings transcript / slide deck are available for color on execution, share‑gains and cost initiatives (important for verifying margin drivers). Henry Schein, Inc. (HSIC) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Market reaction: Despite the beat, some coverage notes the stock edged down as investors may have wanted stronger/raise guidance or clearer upside catalysts — short‑term profit‑taking and comparisons to expectations pressured the share price. Henry Schein beats estimates but stock edges down
• Negative Sentiment: Relative underperformance: Reports highlight the stock underperformed peers on the session, suggesting investors are discriminating between operational beats and forward expectations. Henry Schein Inc. stock underperforms Monday when compared to competitors

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.